Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
NeoGenomics Inc Market Cap
Based on ratings from 9 stock analysts, the NeoGenomics Inc stock price is expected to increase by 26.52% in 12 months. This is calculated by using the average 12-month stock price forecast for NeoGenomics Inc. The lowest target is $16 and the highest is $30. Please note analyst price targets are not guaranteed and could be missed completely.
NeoGenomics Inc has a total of 9 Wall St Analyst ratings. There are 8 buy ratings, 1 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that NeoGenomics Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of NEO.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Mike Matson Needham | Buy | $19 | Reiterates | Jul 30, 2024 |
| Mason Carrico Stephens & Co. | Overweight | $19 | Reiterates | Jul 30, 2024 |
| Bruce Jackson Benchmark | Buy | $18 | Reiterates | Jul 30, 2024 |
| Mark Massaro BTIG | Buy | $21 | Maintains | May 2, 2024 |
| Dan Brennan TD Cowen | Buy | $20 | Maintains | May 1, 2024 |
| Alex Nowark Craig-Hallum | Buy | $26 | Assumes | May 1, 2024 |
| Bruce Jackson Benchmark | Buy | $18 | Reiterates | May 1, 2024 |
| Mike Matson Needham | Buy | $19 | Maintains | Apr 30, 2024 |
| David Westenberg Piper Sandler | Overweight | $20 | Maintains | Feb 26, 2024 |
| Matthew Sykes Goldman Sachs | Buy | $19 | Maintains | Feb 22, 2024 |
| Mike Matson Needham | Buy | $24 | Maintains | Feb 21, 2024 |
| Mark Massaro BTIG | Buy | $21 | Maintains | Dec 29, 2023 |
| Dan Brennan TD Cowen | Outperform | $19 | Maintains | Dec 29, 2023 |
| Mike Matson Needham | Buy | $21 | Reiterates | Dec 28, 2023 |
| Tejas Savant Morgan Stanley | Equal-Weight | $17 | Maintains | Nov 8, 2023 |
| Mike Matson Needham | Buy | $21 | Reiterates | Nov 7, 2023 |
| Tejas Savant Morgan Stanley | Equal-Weight | $16 | Maintains | Oct 24, 2023 |
| Matthew Sykes Goldman Sachs | Buy | $17 | Maintains | Oct 23, 2023 |
| Matthew Sykes Goldman Sachs | Buy | $17 | Maintains | Oct 20, 2023 |
| David Westenberg Piper Sandler | Overweight | $18 | Maintains | Oct 16, 2023 |
When did it IPO
N/A
Staff Count
2,100
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Mr. Christopher Michael Smith BSc
Market Cap
$2.10B
In 2023, NEO generated $591.6M in revenue, which was a increase of 16.07% from the previous year. This can be seen as a signal that NEO's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 11 Sep 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - NeoGenomics will present three studies at the European Society for Medical Oncology Congress in Barcelona from September 13-17, showcasing its research advancements.
Why It Matters - NeoGenomics presenting studies at a major oncology congress could indicate advancements in their research, potentially influencing stock performance and investor interest in the company.
Thu, 29 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - NeoGenomics will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, at 10:45 a.m. ET in New York City.
Why It Matters - NeoGenomics' participation in a prominent healthcare conference highlights its visibility and potential growth, influencing investor sentiment and stock performance.
Mon, 29 Jul 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - NeoGenomics, Inc. (NEO) held its Q2 2024 earnings call, providing insights into financial performance and strategic developments. Further details are available in the transcript.
Why It Matters - NeoGenomics' Q2 2024 earnings call reveals financial performance and strategic insights, impacting stock valuation and future growth expectations for investors.
Mon, 29 Jul 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - NeoGenomics reported its second-quarter results for the period ended June 30, 2024. Further details on financial performance were not provided in the excerpt.
Why It Matters - NeoGenomics' second-quarter results can indicate its financial health and growth trajectory, influencing stock performance and investor sentiment.
Mon, 29 Jul 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - NeoGenomics (NEO) reported revenue and EPS for Q2 2024; investors should compare these figures against Wall Street estimates and year-ago metrics for a comprehensive analysis.
Why It Matters - Comparing NeoGenomics' revenue and EPS to Wall Street estimates and prior year figures helps assess growth potential, market performance, and future investment viability.
Tue, 09 Jul 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - NeoGenomics will release its Q2 2024 financial results on July 29, 2024, after U.S. market close.
Why It Matters - NeoGenomics' upcoming Q2 2024 financial results could impact stock prices, investor sentiment, and market expectations based on performance and guidance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
